Among patients with hormone receptor (HR)-positive, HER2-negative, low-risk ductal carcinoma in situ (DCIS), those who underwent active monitoring had similar two-year invasive ipsilateral breast cancer recurrence rates as those who underwent guideline-concordant treatment, according to results from the COMET clinical trial presented at the San...
American Association for Cancer Research Dec 12 2024 Among patients with hormone receptor -positive, HER2-negative, low-risk ductal carcinoma in situ , those who underwent active monitoring had similar two-year invasive ipsilateral breast cancer recurrence rates as those who underwent guideline-concordant treatment, according to results from the COMET clinical trial presented at the San Antonio Breast Cancer Symposium , held December 10-13, 2024.
All current treatments for DCIS aim to reduce the risk of future invasive cancer, despite a growing body of evidence that not all DCIS is destined to progress. Thus, current practice may result in the overtreatment of women whose tumors are at low risk of progression, leading to chronic pain, altered body image, reduced quality of life, and other side effects that may be avoidable."
The COMET team sought to assess whether active monitoring is as effective as upfront treatment among patients whose DCIS has a low risk of progressing to invasive cancer. They conducted a multicenter, randomized clinical trial that enrolled 995 patients with grade 1 or 2, HR-positive, HER2-negative DCIS with no evidence of invasive cancer.
Related StoriesBecause 29% of patients overall did not adhere to their randomized treatment arm, the researchers performed a separate analysis of 673 patients who received their assigned treatment. The two-year rate of invasive ipsilateral breast cancer was 8.7% in the guideline-concordant care arm and 3.1% in the active monitoring arm.
Cancer Carcinoma Clinical Trial Ductal Carcinoma Endocrine Hormone Mammography Receptor Research Surgery
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Active monitoring for low-risk DCIS results in similar quality of life as standard treatmentPatients with low-risk ductal carcinoma in situ (DCIS) who underwent active monitoring reported comparable physical, emotional, and psychological outcomes to patients who received upfront treatment, according to results from the COMET clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.
Read more »
Tamoxifen lowers breast cancer recurrence in good-risk DCIS patientsFor patients with 'good-risk' ductal carcinoma in situ (DCIS) who underwent breast- conserving surgery and did not receive radiotherapy, tamoxifen significantly decreased the risk of recurrence in the same breast, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.
Read more »
Researchers uncover key genes linked to DCIS progressionA team of researchers mapping a molecular atlas for ductal carcinoma in situ (DCIS) has made a major advance toward distinguishing whether the early pre-cancers in the breast will develop into invasive cancers or remain stable.
Read more »
PATINA trial demonstrates benefit of palbociclib in HR+ HER2+ metastatic breast cancerAlliance Foundation Trials, LLC (AFT) and Pfizer Inc.
Read more »
New CAR T-cell therapy shows promise against aggressive HER2+ breast cancerOne-third of HER2-positive (HER2+) tumors express the P95HER2 protein, which associates with an aggressive form of breast cancer with a poorer prognosis.
Read more »
Imlunestrant offers new hope for ER-positive HER2-negative breast cancerImlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free survival in patients with endocrine therapy-pretreated, ER-positive, HER2-negative advanced breast cancer-;as monotherapy in patients with ESR1 mutations and as combination therapy with abemaciclib (Verzenio) in all patients,...
Read more »